Shulamit Ron-Bigger, the Chief Operating Officer of $AKTS, sold 4,200 shares of the company on 07-08-2026 for an estimated $120,739. We received data on the trade from a recent SEC filing. This was a sale of approximately 100.0% of their shares of this class of stock. Following this trade, they now own 0 shares of this class of $AKTS stock.
$AKTS Insider Trading Activity
$AKTS insiders have traded $AKTS stock on the open market 15 times in the past 6 months. Of those trades, 9 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $AKTS stock by insiders over the last 6 months:
- CAPITAL, LLC ECOR1 has made 2 purchases buying 2,222,222 shares for an estimated $39,999,996 and 0 sales.
- ANSBERT GADICKE purchased 1,112,777 shares for an estimated $20,029,986
- BIOVENTURES 2018, L.P. MPM purchased 1,112,777 shares for an estimated $20,029,986
- HELEN SUSAN KIM has made 2 purchases buying 835,000 shares for an estimated $15,030,000 and 0 sales.
- VENTURES II, LLC VIDA has made 2 purchases buying 835,000 shares for an estimated $15,030,000 and 0 sales.
- TODD FOLEY purchased 232,870 shares for an estimated $4,191,660
- AKOS CZIBERE (Chief Medical Officer) has made 0 purchases and 3 sales selling 50,000 shares for an estimated $1,388,701.
- SHULAMIT RON-BIGGER (Chief Operating Officer) has made 0 purchases and 3 sales selling 50,000 shares for an estimated $1,387,557.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$AKTS Hedge Fund Activity
We have seen 60 institutional investors add shares of $AKTS stock to their portfolio, and 0 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MPM BIOIMPACT LLC added 4,835,872 shares (+inf%) to their portfolio in Q1 2026, for an estimated $86,513,750
- ECOR1 CAPITAL, LLC added 4,824,469 shares (+inf%) to their portfolio in Q1 2026, for an estimated $86,309,750
- BLUE OWL CAPITAL HOLDINGS LP added 3,161,348 shares (+inf%) to their portfolio in Q1 2026, for an estimated $56,556,515
- WELLINGTON MANAGEMENT GROUP LLP added 2,317,044 shares (+inf%) to their portfolio in Q1 2026, for an estimated $41,451,917
- BLACKROCK, INC. added 2,112,127 shares (+inf%) to their portfolio in Q1 2026, for an estimated $37,785,952
- RTW INVESTMENTS, LP added 1,592,043 shares (+inf%) to their portfolio in Q1 2026, for an estimated $28,481,649
- PRICE T ROWE ASSOCIATES INC /MD/ added 1,564,196 shares (+inf%) to their portfolio in Q1 2026, for an estimated $27,983,466
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$AKTS Analyst Ratings
Wall Street analysts have issued reports on $AKTS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- William Blair issued a "Outperform" rating on 04/29/2026
To track analyst ratings and price targets for $AKTS, check out Quiver Quantitative's $AKTS forecast page.
$AKTS Price Targets
Multiple analysts have issued price targets for $AKTS recently. We have seen 4 analysts offer price targets for $AKTS in the last 6 months, with a median target of $33.0.
Here are some recent targets:
- Christopher Raymond from Raymond James set a target price of $40.0 on 06/16/2026
- Robert Burns from HC Wainwright & Co. set a target price of $35.0 on 06/02/2026
- An analyst from Leerink Partners set a target price of $31.0 on 02/03/2026
- Jessica Fye from JP Morgan set a target price of $30.0 on 02/03/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
